BERLIN (Reuters) -German pharma company Bayer reported positive study results for its anticoagulant asundexian on Sunday, two years after a research setback for the promising blood thinner candidate.
In a Phase III study, a daily dose of 50 milligrams significantly reduced the risk of ischemic stroke compared with a placebo, Bayer said.
Detailed results from the OCEANIC-STROKE study will be presented at an upcoming scientific congress, said Bayer.
Bayer added that it plans to speak with health authorities worldwide in preparation for the submission of marketing authorisation applications.
Bayer had originally predicted that asundexian would have peak sales potential of more than 5 billion euros ($5.76 billion) - more than any of its other drugs.
At the end of 2023, the company had a major setback with the drug after it failed in a pivotal clinical trial involving patients with atrial fibrillation and a risk of stroke.
($1 = 0.8687 euros)
(Reporting by Joern Poltz. Writing by Miranda Murray. Editing by Jane Merriman)
5 Advancement Developments in Biotechnology- Iran war drives global fertilizer prices up, raising food cost fears
- OECD: Iran war dampening global growth
- Different Film Classification: What's Your Go-To for Amusement
- 12 Once-In-A-Lifetime Travel Experiences To Add to Your Bucket List
- How one man's concern saved his brothers from heart disease
- Anti-war protests held across Israel under wartime gathering limits
- Gulf countries roll out more autonomous taxis
- New Jordan security fence could be done in early 2028
